Wickramasekara: Applying standard data practices to life sciences requires little domain expertise
Sajith Wickramasekara · Drug Discovery as a Data Problem // Sajith Wickramasekara, Benchling (FirstMark's Data Driven) · Feb 3, 2017 · at 12:51
Sajith Wickramasekara is the founder and CEO of Benchling, a software platform for life science research and antibody discovery.
0:00 / 0:10exact quote · 10.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Using quite standard data practices we were able to make a big dent in a really high impact field that touches everyone and it doesn't require a ton of domain expertise.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Sajith Wickramasekara
Wickramasekara: Clunky enterprise systems force pharma scientists to email sensitive IP
“A lot of these companies, they do have systems that exist, but they're quite clunky and not integrated. So the scientists resort to using email, and this is whatever email systems they have set up. Sometimes they're personal gmails as well.”
Wickramasekara: Advanced drug development lacks modern software and data infrastructure
“You would think that such deliberate advanced science would have a large amount of software and advanced data behind it as well, but that's actually not the case.”
Wickramasekara: Curing cancer with Excel is worse than dev without version control
“They're literally trying to cure cancer using Excel. This is the equivalent of one of the companies you work at building software without version control. It's honestly probably a little worse, actually.”
Wickramasekara: Life science research still runs on paper, email, and Excel
“This is an industry that runs on paper, email, and Excel, and it's something that touches everyone.”